Young Scientist Award 2007

  • Bennie Repsold North-West University
  • Jacobus P Petzer North-West University
  • Jacobus J Bergh North-West University
  • Sarel F Malan North-West University

Abstract

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most frequent neurodegenerative disorders and cause of disability among western societies. Interest in the selective inhibition of monoamine oxidase B (MAO-B) has increased in the last years due to their therapeutic potential in this age related neurodegeneration. Currently, acetyl cholinesterase (AChE) inhibitors are the only drugs approved for treatment of cognitive dysfunction in AD and dopamine (DA) replacement therapy with levodopa (L-Dopa) in conjunction with irreversible MAO-B inhibitors (e.g. Deprenyl) is the present first-line treatment regime in PD.

Author Biographies

Bennie Repsold, North-West University
Pharmaceutical Chemistry, School of Pharmacy
Jacobus P Petzer, North-West University
Pharmaceutical Chemistry, School of Pharmacy
Jacobus J Bergh, North-West University
Pharmaceutical Chemistry, School of Pharmacy
Sarel F Malan, North-West University
Pharmaceutical Chemistry, School of Pharmacy
Published
2008-03-07
Section
Cum Laude